Achieve Life Sciences, Inc. (ACHV)Healthcare | Biotechnology | Bothell, United States | NasdaqCM
6.10 USD
-0.01
(-0.164%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 6.11 +0.01 (0.164%) ⇧ (July 13, 2026, 6:55 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:04 a.m. EDT
The long-term outlook remains deeply bearish due to a catastrophic multi-year price collapse of nearly 99.9%, driven by eight consecutive years of negative annual returns. While the company recently joined the Russell 2000 index and analysts have upgraded their stance following a clinical trial readout, the market has punished the stock severely, with the latest year seeing a precipitous 52% drop. Fundamentals are deteriorating, with negative earnings, negative free cash flow, and a return on equity of nearly -5%. The balance sheet is fragile, carrying significant debt against minimal book value. Although the short-term price action shows a bounce off lows, the statistical forecast model offers no confidence in a reversal, predicting a slight further decline over the next month. The options market confirms this skepticism, with traders aggressively buying deep out-of-the-money puts as insurance against further downside. Without a proven path to profitability or a clear turnaround in revenue growth, the risk of permanent capital loss outweighs the speculative upside. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.165212 |
| MSTL | 0.171129 |
| AutoETS | 0.175127 |
| AutoARIMA | 0.291228 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 3.59 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.358 |
| Excess Kurtosis | -1.04 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 140.026 |
| Market Cap | 626,220,224 |
| Forward P/E | -12.34 |
| Beta | 2.22 |
| Website | https://www.achievelifesciences.com |
As of July 11, 2026, 6:04 a.m. EDT: Speculators are positioned for continued weakness, evidenced by massive open interest in out-of-the-money puts relative to calls across all expirations. The put/call ratio is heavily skewed toward downside protection, while call volume is concentrated in strikes significantly above the current price, indicating a lack of immediate bullish conviction despite the recent rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.2218182 |
| Address1 | 22,722 29th Dr. SE |
| Address2 | Suite 100 |
| All Time High | 1,856,250.0 |
| All Time Low | 1.84 |
| Ask | 7.62 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 3,186,760 |
| Average Daily Volume3 Month | 2,089,609 |
| Average Volume | 2,089,609 |
| Average Volume10Days | 3,186,760 |
| Beta | 2.217 |
| Bid | 4.42 |
| Bid Size | 2 |
| Book Value | 0.201 |
| City | Bothell |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.1 |
| Current Ratio | 2.625 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 6.165 |
| Day Low | 5.9504 |
| Debt To Equity | 140.026 |
| Display Name | Achieve Life Sciences |
| Dividend Date | 1,596,153,600 |
| Earnings Call Timestamp End | 1,778,589,000 |
| Earnings Call Timestamp Start | 1,778,589,000 |
| Earnings Timestamp | 1,778,589,000 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | -52,226,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -11.716 |
| Enterprise Value | 611,903,232 |
| Eps Current Year | -0.68444 |
| Eps Forward | -0.49444 |
| Eps Trailing Twelve Months | -1.07 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.3506 |
| Fifty Day Average Change | 0.74940014 |
| Fifty Day Average Change Percent | 0.14005908 |
| Fifty Two Week Change Percent | 122.18182 |
| Fifty Two Week High | 7.11 |
| Fifty Two Week High Change | -1.0100002 |
| Fifty Two Week High Change Percent | -0.14205347 |
| Fifty Two Week Low | 2.37 |
| Fifty Two Week Low Change | 3.73 |
| Fifty Two Week Low Change Percent | 1.5738398 |
| Fifty Two Week Range | 2.37 - 7.11 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 813,504,600,000 |
| Float Shares | 87,466,543 |
| Forward Eps | -0.49444 |
| Forward P E | -12.33719 |
| Free Cashflow | -26,947,124 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 28 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0093 |
| Held Percent Institutions | 0.63632 |
| Implied Shares Outstanding | 102,659,057 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.oncogenex.com/index.cfm |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,596,153,600 |
| Last Split Factor | 1:20 |
| Long Business Summary | Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington. |
| Long Name | Achieve Life Sciences, Inc. |
| Market | us_market |
| Market Cap | 626,220,224 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_415241078 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -51,989,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 627,246,838 |
| Number Of Analyst Opinions | 10 |
| Open | 6.06 |
| Operating Cashflow | -45,309,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Peg Ratio | 17.68 |
| Phone | 604 210 2217 |
| Post Market Change | 0.010000229 |
| Post Market Change Percent | 0.16393818 |
| Post Market Price | 6.11 |
| Post Market Time | 1,783,983,323 |
| Previous Close | 6.11 |
| Price Eps Current Year | -8.9123955 |
| Price Hint | 2 |
| Price To Book | 30.348257 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.474 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0100002 |
| Regular Market Change Percent | -0.16367 |
| Regular Market Day High | 6.165 |
| Regular Market Day Low | 5.9504 |
| Regular Market Day Range | 5.9504 - 6.165 |
| Regular Market Open | 6.06 |
| Regular Market Previous Close | 6.11 |
| Regular Market Price | 6.1 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 1,326,816 |
| Return On Assets | -1.08432 |
| Return On Equity | -4.9614897 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 102,659,057 |
| Shares Percent Shares Out | 0.122600004 |
| Shares Short | 12,582,151 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 7,675,144 |
| Short Name | Achieve Life Sciences, Inc. |
| Short Percent Of Float | 0.1232 |
| Short Ratio | 4.92 |
| Source Interval | 15 |
| State | WA |
| Symbol | ACHV |
| Target High Price | 21.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 13.8 |
| Target Median Price | 12.0 |
| Total Cash | 29,269,000 |
| Total Cash Per Share | 0.285 |
| Total Debt | 14,952,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.07 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.5417 |
| Two Hundred Day Average Change | 1.5583 |
| Two Hundred Day Average Change Percent | 0.34310943 |
| Type Disp | Equity |
| Volume | 1,326,816 |
| Website | https://www.achievelifesciences.com |
| Zip | 98,021 |